Packaging Goes Green - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Packaging Goes Green
Pharmaceutical companies get ideas for sustainable packaging from other industries.


Pharmaceutical Technology
Volume 33, Issue 10

Degradable PET controversy

Another material receiving lots of attention, degradable PET, sounds like an ideal choice for green packaging because so much PET packaging ends up as litter, ocean pollution, or in landfills. Three trade associations have reservations about this PET, which includes additives to make it degradable. The associations fear that the material could cause problems for PET recycling and recycled-content PET products.

NAPCOR contends that suppliers of degradable PET need to substantiate claims of degradability, investigate the effect of degradable additives on the quality of the PET recycling stream, examine the effects of degradable additives on products made of RPET, and learn how the material changes the service life of these products.

"We don't yet understand the impacts that these additives could have on the quality of the PET recycling stream, let alone the impacts on the safety and functionality over time of next-use PET products like recycled-content PET packaging, carpeting, or strapping," explains Sabourin.

EurPR (Brussels), a trade association for plastics recyclers, echoes NAPCOR's concerns and is particularly worried about whether oxo-biodegradable PET will pose problems in recycling operations.

European Bioplastics (Berlin) also has issued warnings about oxo-biodegradable plastic containers, claiming that no evidence shows that these materials meet international standards regarding biodegradation and compostability such as the International Organization for Standardization's ISO 17088 Specifications for Compostable Plastics or European Norm 13432 Requirements for Packaging Recoverable through Composting and Biodegradation. "If certain products that claim to be biodegradable or compostable are proven not to fulfill acknowledged standards, this is liable to impact negatively on our own members' products, even though they do fully comply," explains Andy Sweet-man, chairman of the board of European Bioplastics.

But a maker of oxo-biodegradable additives argues that its material complies with the degradability, biodegradability, and nonecotoxicity requirements of the American Soceity for Testing and Materials's D6954-04 Standard Guide for Exposing and Testing Plastics that Degrade in the Environment by a Combination of Oxidation and Biodegradation (Symphony Environmental Technologies, London).

Another maker of a degradable additive also claims compliance with ASTM standards for biodegradability and recyclability and has confirmed results with third-party testing and validation. This additive is not classified as oxo-biodegradable, but enables the PET to degrade in anaerobic and aerobic environments by attracting microbes that convert the resin into humus and gases such as carbon dioxide and methane. Because it does not chemically bond to the PET, it reportedly has no effect on bottle weight or properties. Testing also has shown that the material has no negative effect on the PET recycling stream (EcoPure degradable additive for PET, ENSO Bottles, Phoenix, AZ).

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here